BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8143493)

  • 1. Anti-CD3 and -CD4 monoclonal antibody in the treatment of steroid-resistant renal allograft rejection.
    Wang XH; Xie T
    Chin Med J (Engl); 1993 Nov; 106(11):821-4. PubMed ID: 8143493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting therapeutic effect of anti-CD3 and CD4 monoclonal antibody in acute renal allograft rejection.
    Wang XH; Xie T
    Transplant Proc; 1996 Jun; 28(3):1306-8. PubMed ID: 8658671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.
    Abbs IC; Clark M; Waldmann H; Chatenoud L; Koffman CG; Sacks SH
    Ther Immunol; 1994 Dec; 1(6):325-31. PubMed ID: 7584508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Orthoclone OKT3 in the treatment of intractable acute renal allograft rejection].
    Yu LX
    Zhonghua Wai Ke Za Zhi; 1993 Dec; 31(12):754-5. PubMed ID: 8033708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients.
    Posselt AM; Vincenti F; Bedolli M; Lantz M; Roberts JP; Hirose R
    Transplantation; 2003 Jul; 76(1):190-5. PubMed ID: 12865808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OKT3 treatment of steroid- and/or anti-thymocyte globulin-resistant renal allograft rejection occurring on triple baseline immunosuppression including cyclosporine A.
    Widmer U; Frei D; Keusch G; Burger HR; Largiader F; Binswanger U
    Transplant Proc; 1988 Oct; 20(5 Suppl 6):90-5. PubMed ID: 3140454
    [No Abstract]   [Full Text] [Related]  

  • 7. [OKT3 treatment of refractory renal allograft rejection].
    Xu J; Ma J; Bai X
    Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of allograft rejection by anti-T-cell receptor-alpha beta monoclonal antibodies preserving resistance to bacterial infection.
    Eto M; Yoshikai Y; Nishimura Y; Hiromatsu K; Maeda T; Nomoto K; Kong YY; Kubo RT; Kumazawa J; Nomoto K
    Immunology; 1994 Feb; 81(2):198-204. PubMed ID: 8157269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of steroid-resistant renal allograft rejection with OKT3 and plasmapheresis.
    Haberal M; Sert S; Gülay H; Arslan G; Bilgin N
    Transplant Proc; 1990 Aug; 22(4):1761-3. PubMed ID: 2117801
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-CD4 monoclonal antibody therapy of late acute rejection in renal allograft recipients--CD4+ T cells play an essential role in the rejection process.
    Reinke P; Kern F; Fietze E; Döcke WD; Ewert R; Emmrich F; Volk HD
    Transplant Proc; 1995 Feb; 27(1):859-62. PubMed ID: 7879207
    [No Abstract]   [Full Text] [Related]  

  • 11. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
    Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neurologic complications induced by the treatment of the acute renal allograft rejection with the monoclonal antibody OKT3].
    Fernández O; Romero F; Bravo M; Burgos D; Cabello M; González-Molina M
    Neurologia; 1993 Oct; 8(8):277-80. PubMed ID: 8240843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One center's experience with antithymocyte globulin treatment for acute rejection in renal transplantation.
    Colak T; Sevmiş S; Karakayali H; Moray G; Haberal M
    Transplant Proc; 2008; 40(1):123-5. PubMed ID: 18261564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Devising murine models to better adapt clinical protocols: sequential low-dose treatment with anti-CD3 and anti-CD4 monoclonal antibodies to prevent fully mismatched allograft rejection.
    Campos HH; Bach JF; Chatenoud L
    Transplant Proc; 1993 Feb; 25(1 Pt 1):798-9. PubMed ID: 8438486
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells.
    Xia G; He J; Zhang Z; Leventhal JR
    Transplantation; 2006 Dec; 82(12):1749-55. PubMed ID: 17198271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation.
    van Son WJ; van den Berg AP; The TH; Tegzess AM
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1436-8. PubMed ID: 8382873
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute renal allograft rejection: the role of monoclonal antibodies in treatment: experience with orthoclonal anti-T3 cell antibody.
    McLigeyo SO; Notghi A; Anderton JL; Dick J
    East Afr Med J; 1990 Sep; 67(9):667-73. PubMed ID: 2123786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
    Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
    Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3).
    Noël C; Hazzan M; Coppin MC; Pruvot FR; Bridoux F; Lelièvre G
    Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870
    [No Abstract]   [Full Text] [Related]  

  • 20. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.